WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MLYS

Based on 1 analyst offering 12 month price targets for Mineralys Therapeutics Inc.
Min Forecast
$30.00+165.72%
Avg Forecast
$30.00+165.72%
Max Forecast
$30.00+165.72%

Should I buy or sell MLYS stock?

Based on 1 analyst offering ratings for Mineralys Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MLYS stock forecasts and price targets.

MLYS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-02

1 of 1

Forecast return on equity

Is MLYS forecast to generate an efficient return?

Forecast return on assets

Is MLYS forecast to generate an efficient return on assets?

MLYS revenue forecast

What is MLYS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$276.4M
Avg 2 year Forecast
$612.8M
Avg 3 year Forecast
$1.1B

MLYS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MLYS$11.29$30.00+165.72%Strong Buy
STOK$12.05$21.60+79.25%Buy
CALT$18.70$50.00+167.38%Buy
NVAX$3.97$19.00+378.59%Buy
OLMA$9.93$22.50+126.59%Strong Buy
View Top Biotech Stocks

Mineralys Therapeutics Stock Forecast FAQ

Is Mineralys Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MLYS) stock is to Strong Buy MLYS stock.

Out of 1 analyst, 1 (100%) are recommending MLYS as a Strong Buy, 0 (0%) are recommending MLYS as a Buy, 0 (0%) are recommending MLYS as a Hold, 0 (0%) are recommending MLYS as a Sell, and 0 (0%) are recommending MLYS as a Strong Sell.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.

What is MLYS's revenue growth forecast for 2027-2029?

(NASDAQ: MLYS) Mineralys Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Mineralys Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MLYS's revenue for 2027 to be $13,716,067,101, with the lowest MLYS revenue forecast at $13,716,067,101, and the highest MLYS revenue forecast at $13,716,067,101. On average, 1 Wall Street analysts forecast MLYS's revenue for 2028 to be $30,411,492,677, with the lowest MLYS revenue forecast at $30,411,492,677, and the highest MLYS revenue forecast at $30,411,492,677.

In 2029, MLYS is forecast to generate $52,904,333,936 in revenue, with the lowest revenue forecast at $52,904,333,936 and the highest revenue forecast at $52,904,333,936.

What is MLYS's forecast return on assets (ROA) for 2027-2027?

(NASDAQ: MLYS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is MLYS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MLYS price target, the average MLYS price target is $30.00, with the highest MLYS stock price forecast at $30.00 and the lowest MLYS stock price forecast at $30.00.

The Wall Street analyst predicted that Mineralys Therapeutics's share price could reach $30.00 by Apr 2, 2025. The average Mineralys Therapeutics stock price prediction forecasts a potential upside of 165.72% from the current MLYS share price of $11.29.

What is MLYS's forecast return on equity (ROE) for 2027-2027?

(NASDAQ: MLYS) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.